Investors Purchase High Volume of Maravai LifeSciences Put Options (NASDAQ:MRVI)

Key Points

• Stock traders have notably increased their purchase of put options for Maravai LifeSciences, with a significant rise of 1,791% in volume, totaling 1,002 put options traded.
• Analysts have revised their target prices for Maravai LifeSciences, with Craig Hallum setting a target of $10.00 and Royal Bank of Canada lowering it to $5.00, indicating varied sentiments among experts.
• As of Thursday, Maravai LifeSciences shares have experienced a 2.0% decline, currently trading at $2.46, with a market capitalization of approximately $626.46 million.

Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI - Get Free Report) was the recipient of some unusual options trading on Wednesday. Investors bought 1,002 put options on the company. Thisrepresentsanincreaseofapproximately1,791% compared to the typical daily volume of 53 put options.

Maravai LifeSciences Trading Up 0.8%

MRVI stock traded up $0.02 during trading on Tuesday, reaching $2.42. 626,517 shares of the stock traded hands, compared to its average volume of 1,537,351. The business's 50 day moving average price is $2.46 and its 200-day moving average price is $2.46. Maravai LifeSciences has a 52-week low of $1.66 and a 52-week high of $9.60. The company has a debt-to-equity ratio of 0.68, a current ratio of 5.16 and a quick ratio of 4.49. The firm has a market capitalization of $617.97 million, a PE ratio of -1.78 and a beta of 0.28.

Wall Street Analysts Forecast Growth

A number of brokerages have commented on MRVI. Robert W. Baird lowered their target price on Maravai LifeSciences from $3.00 to $2.00 and set a "neutral" rating on the stock in a report on Tuesday, May 13th. Craig Hallum decreased their price objective on Maravai LifeSciences from $12.00 to $10.00 and set a "buy" rating on the stock in a report on Tuesday, May 13th. Finally, Royal Bank Of Canada decreased their price objective on Maravai LifeSciences from $7.00 to $5.00 and set an "outperform" rating on the stock in a report on Tuesday, August 12th. Four equities research analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, Maravai LifeSciences presently has a consensus rating of "Hold" and an average target price of $5.75.

Institutional Investors Weigh In On Maravai LifeSciences

A number of institutional investors have recently added to or reduced their stakes in MRVI. Wells Fargo & Company MN grew its position in Maravai LifeSciences by 39.8% during the fourth quarter. Wells Fargo & Company MN now owns 52,685 shares of the company's stock valued at $287,000 after acquiring an additional 15,001 shares during the period. Bank of Montreal Can purchased a new stake in Maravai LifeSciences during the fourth quarter valued at about $423,000. Townsquare Capital LLC purchased a new stake in Maravai LifeSciences during the fourth quarter valued at about $103,000. Barclays PLC raised its position in Maravai LifeSciences by 12.5% in the fourth quarter. Barclays PLC now owns 207,292 shares of the company's stock valued at $1,129,000 after purchasing an additional 23,103 shares during the period. Finally, XTX Topco Ltd raised its position in Maravai LifeSciences by 64.2% in the fourth quarter. XTX Topco Ltd now owns 38,188 shares of the company's stock valued at $208,000 after purchasing an additional 14,936 shares during the period. Hedge funds and other institutional investors own 50.25% of the company's stock.

Maravai LifeSciences Company Profile

Maravai LifeSciences Holdings, Inc, a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species.